Pituitary adenomas are benign tumors; they arise from epithelial pituitary cells and they represent 10-15% of intracranial tumors. They can be found at 3% up to 20% of the population, on autopsy series. Cephalalgia is a precocious symptom whichkeeps going over the disease. The aspect as a whole of the person who suffers from this disease in the phase of established malady is characteristic: a very flat-shaped body, massive and stubby thus justifying the comparison with a pachyderm. Hands and legs are disproportionally bigger, like paddles, facies is disharmonic, facial features become coarse, with oblate forehead and massive prominent pregnant mandible. The joints disproportionately bigger, have limited, painful movement. The patient also presents visceral hypertrophy with numerous dysfunctions from various apparatus and systems.

**Experimental part**

This study was performed at Craiova Emergency County Hospital, having a retrospective component (after observation files) and a perspective one (by direct supervision), over a 6 years period [9]. Within the study there were included 80 patients with pituitary adenomas - 27 prolactinomas, 19 GH secreting adenomas and 34 non-secreting tumors.

The patients were investigated by determining the STH, taking usual blood analyses and also evaluating the breathing function and making a cardiovascular, neurological, ophthalmological, psychological evaluation and CT or RMN examination of the GH secreting pituitary tumor. For the 19 patients diagnosed with acromegaly, GH dosing was performed, resulting in values higher than the upper limit (ie above 5ng/mL in men or over 10ng/mL in women).

Although the high diagnostic accuracy of IGF1 (greater than baseline GH) is known, we did not have this possibility in our study. There are cases of normal and elevated IGF1 acromegaly in the literature. This imposes the introduction of this criterion as a method routine in studying acromegaly.

After some authors with experience in the management of patients with acromegaly, diagnosis can only be missed if only criteria based on GH values are used. For diagnosis and monitoring of acromegals, GH should be used along with the serum titer of IGF1 [10].

In acromegaly patients, GH media was 20.96ng/mL, with a minimum of 6.8ng/mL and a maximum of 72.7ng/mL.

It is described in literature the inconsistency between GH (sometimes small) values and clinical appearance.

**Dosing technique - methods for dosing the straight (hormone of growth)**

hGH (somatotropin) is essential in the growth process, and in adults it plays an important role in metabolic activities. It is synthesized in the acidophilic cells of the anterior pituitary and its secretion from the intracellular storage granules is regulated by hormone-releasing hormone (GHRH) hormones and SRAT (somatotropin release-inhibiting factor); their synthesis depends on neurotransmitters, such as serotonin, dopamine, norepinephrine, and growth hormone releasing peptides. It is also secreted in response to effort, stress, deep sleep, hypoglycemia, glucagon, insulin, thyroid hormones,
estrogen, testosterone and vasopressin. Plasma exists in several monomeric and oligomeric isoforms (big GH and big big GH). Circulating GH-binding protein, which is similar to the extracellular domain of the tissue receptor of hGH5.

hGH stimulates the production of RNA, protease synthesis, mobilizes fatty acids from deposits and has transient insulin antagonist effects; elevated prolonged levels may induce alteration of glucose tolerance [5].

The secretion of hGH is pulsatile, but in adults plasma concentrations are stable, hGH oscillations are attenuated by GHBP. The plasma half-life is 20 min [5]. If the pituitary secretion of hGH is deficient or excessive in different stages of growth, it will determine the occurrence of nanism and gigantism. An excess of adult growth hormone will generate acromegaly.

The test is useful for confirming hypo- or hyper-pituitarism, so that appropriate therapy can be initiated as soon as possible.

Determination of the hormone can be performed under both basal and post stimulation conditions (exercise, arginine, glucagon or insulin) or suppression (after 100 g of glucose).

Absence of response or inadequate response to stimulation tests is associated with hypopituitarism.

In case of gigantism or acromegaly, there is a lack of suppression or incomplete suppression after glucose administration. Furthermore, patients with acromegaly may have paradoxical increases in hGH in the suppression test1.

Patient training - junction (fasting) and after at least 30 minutes of rest, to determine the basal concentration3; Harvested specimen - venous blood 3 Vacuum container without anticoagulant, with / without separator gel.

Processing required after harvest - separate the serum by centrifugation; work the serum immediately; if this is not possible, the serum freezes.

Sample volume - minimum 0.5 mL ser.

Method - immunoenzymatic with chemiluminescent detection.

Reference values - are age and sex dependent (table 1).

| Age and sex | Reference values (ng / mL) |
|-------------|----------------------------|
| Adults • Women <60 anni | 1-14 |
| • Women >60 anni | 10 |
| • Men <60 anni | <5 |
| • Men >60 anni | 0.4-10 |
| Newborns | 15-40 |
| Children | <20 |
| After stimulation | > 5 (growth compared to basal level) |
| After suppression | > 10 (maximum response to basal level) |

Conversion factor: ng / mL = µg / L.

Detection limit - 0.01ng / mL

Limits and interferences

A single determination of hGH has a limited value due to marked fluctuations in serum concentration. Stimulation or suppression tests provide much more information.

Elevated levels can be met postprandial, after physical activity, deep sleep, stress, anxiety, sex hormone deficiency, especially androgens, hypo-, hyperthyroidism, adrenal hyperfunction, increased levels of free fatty acids; low levels can occur in hunger, cachexia, protein deficiency, metabolic imbalance diabetes.

Results and discussions

Recent studies mention a 1/1 women/men proportion for the GH secreting adenomas, but in this study we registered 11 women and 8 men with GH secreting adenomas (fig. 1).

Regarding distribution on age groups specific studies showed that the occurrence of investigated pathology is more frequent for the age group of 40 - 60 years. In our study we found 4 cases (5%) with ages between 40 - 49 years, 7 cases (8.75%) with ages between 50 - 59 years, and only 3 cases (3.75%) with ages between 30 - 39 years, no patient below 30 years and the rest of 5 cases with ages over 60 years (fig. 2). As for the 19 patients diagnosed with acromegaly there has been performed GH dosing and as a result there were higher values than the upper limit (over 5ng/mL for men or over 10ng/mL for women). At the acromegalic patients The GH average was 20.96ng/mL, with a minimum of 6.8ng/mL and a maximum of 72.7ng/mL.

From the graphic below (fig.3) we can conclude that there is a direct correlation between the dimension of the tumor measured RMN and somatotrope secretion (the bigger diameter of the tumor is, the bigger is the quantity

Fig 1. Gender and pathology distribution of subjects in the tumor group

Fig 2. Distribution by age group of the tumor group
because the line of regression has a clear upward slope. This is underlined also statistically, the r correlation coefficient of Pearson having the value of 0.752, which overcomes the limit of significance of ±0.456 of r for 19 subjects (17 freedom degrees). Within the acromegaly patients group we have obtained the following pathological values (fig.4):

- Systolic HTA at 8 patients (57.9%) and diastolic HTA at 1 patient (5.3%);
- AV over 80 beats /min at 1 patient (5.3%);
- Glyceremia over 110 mg/dL at 2 patients (10.5%), with diabetes mellitus type II confirmed at 1 patient;
- Hypercholesterolemia at 9 patients (47.4%);
- Hypertriglyceridemia (triglycerides over 150 mg) at 5 patients (26.3%);
- 11 patients (57.9%) had GH secretive macroadenoma GH and 8 patients (42.1%) had microadenoma (smaller than 10 mm diameter).

Regarding the patients from the present study, the percentage of those whose visual field was affected (8.75% representing 7 patients) is comparable to that whose patients didn’t have any CV deficits-8 patients and visual acuity decrease was registered at 46.25% of the acromegalic patients [16].

From the 19 patients diagnosed with acromegaly, only 1 patient didn’t have an EKG print, 4 patients (5%) had cardiomegaly with associative ischemic cardiopathy, 5 patients (6.25%) had ischemic cardiopathy symptoms but 9 patients (11.25%) had an EKG track of normal repose. [15]study there can be seen a three times growth of mortality from breathing causes. Functional breathing tests are abnormal not only at men but also at women. Total pulmonary capacity increases up to 81% at men and 56% at women, 36% present a narrowing of small pipes and 26% have their large bronchias narrowed. (155) Pipes’ narrowing and apnea during sleeping, frequent at these patients, contributes to a high level of mortality at acromegalic patients [11,12]. In this study, 18 patients out of 19, took the breathing functional exploration test. Patients were tested by using spirometric method, measuring the maximum exhaling volume per second (MEVS). After measuring the MEVS there resulted: 10 patients (52% of acromegalic people) didn’t have a ventilation dysfunction of gentle obstructive type and 2 patients (11%) had a medium ventilation dysfunction [13]. Depressive disorders and other kinds of disorders associated to acromegaly were: 10% of GH secretive pituitary tumor had a severe depression (closely related to present dysmorphism at these patients) 6.25% had an average depression, 5% a light depression and only 2.5% didn’t present any symptoms of depression. The risk of depression at the acromegalic patients is higher than the risk of this psychiatric manifestation at other pituitary affections. Other symptoms noticed at acromegalic patients were: psycho-emotional lability, physical and psychical asthenia, loss of initiative, inhibition, tendency of social isolation, menest and prosex difficulties, insomnia/terrifying dreams, irritability, depressive ideation, panic attack, fatigue, anxiety, hallucinations [14].
Conclusions

As for the frequency, adenoma secreted by GH represents the second type of pituitary adenoma after prolactinoma being characterized by clinical dysmorphism and multivisceral affectionation.

Within the studied group we had 11 women and 8 men with a frequent incidence of age group 40-60 years.

There was a direct correlation between the dimension of the tumor measured RMN and somatotrope secretion (the larger is the diameter of the tumor the bigger is the quantity of the hormone).

85% of the patients had systolic HTA, 1 patient (5.3%) had HTA diastolic, diabetes mellitus type 2 was found at 1 patient and dyslipidemia was presented at 9 patients.

References

1. BISTRICEANU, M., Endocrinologie clinica, Ed. de Sud, Craiova, 2000.
2. DORSHKIND, K., HORSEMAN ND. The roles of prolactin, growth hormone, insulin-like growth factor-1, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000 Jun; 21:292-312.
3. DIMARAKI, EV., JAFFEE, CA., DEMOTT, FRIBERG R., ET ALL Acromegaly apparently normal Gh secretion: implication for diagnosis foolow up. J Clin Endocrinol Metab 2002;87:3537-3542.
4. FREA PU, REYES CM, NURUZZAMAN AT, ET AL. Basal and glucosuppressed GH levels less than 1 µg/L in newly diagnosed acromegaly. Pituitary 2003;6:175-180.
5. HERRMANN, B.L., BRUCH, C., SALLER, B., BARTEL, T., FERDIN, S., ERBEL, R., MANN, K: Acromegaly evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy. Clin Endocrinol 2002;56:595-602.
6. JAFFRAIN-REA, ML., MORONI, C., BALDELLI, R., ET AL: Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology (Oxf), 2003;54(2): 189-195. Ref. Type: Generic.
7. KATZNELSON, LAURANCE: The diagnosis and treatment of acromegaly. The endocrinologist. 2003;13:428-434.
8. ORUÇKAPAN, H.H., SENMEVISM, O., OZCAN, OE., ET AL: Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg Neurol 2000, 53:211-219.
9. POPOVIC, V., LEAL, A., MICIC, D., ET AL. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 2000;356:1137-1142.
10. IONESCU, E., Teza de doctorat-Evaluarea capacitatii de munca la pacientii cu patologie hipofizara.Craiova 2011.
11. IONESCU, E., Ghid de evaluare clinic-biologica a pacientilor cu patologie hipofizara, Editura Techirghiol Craiova 2015.
12. MIHAELA, N., POPESCU, ELENA, IONESCU, L. C. ,IONESCU, B. V., COTOI, A.I. POPESCU, ANCA, ,ELENA, GANESCU, ,ADINA, GLODEANU, ,CRISTINA, GEORGIANU ,ANDREIANA,MORARU, ANCA, PÂTRASCU, Clinical aggression of prolactinomas: correlations with invasion and recurrence, Romanian Journal of Morphology Embryology, Romanian Academy Publishing House, Volume 54, 2013, ISSN (print) 1220-0522, ISSN (on line) 2066-8279.
13. GANESCU,A., MURESEAN, M., IONESCU, E., et all, New Methods for Claritine Determination Based on Pt(IV) Complex Anions, Rev.Chim.(Bucharest), 65 , no,5, 2014, p. 512-515.
14. MAVRITSAKIS, NIKOLAOS., URSU, VASILE EMIL., IONESCU, ANCA GANESCU, Actual Study Regarding Quantitative Determination of Tetracyclines by Electrical Analysis Techniques and Methods Potentiometric sensors for tetracycline Rev.Chim.(Bucharest), 70, no. 2,2019, p. 671-675.
15. MAVRITSAKIS, N., URSU, VE., IONESCU, E., GANESCU, A., Clinical and Biological Study on the Relevance of Hiperfibrinogenemyme in Cardiovascular Pathology of the Obez Patient, Rev.Chim. (Bucharest), 70, no. 3, 2019, p. 950-955.
16. POPESCU, J.G., SECHEL,G., ,LEASU,F.G., TANTU., M.M.,COTOI, B.V., ROGOZEA, L.M.,Correlations on the protection of personal data and intellectual property rights in medical research,Rom.J. Morphol.Embryol,59(3),2018,pag 1001-1005.

Manuscript received: 6.11.2018